title: Central and peripheral administration of amylin induces energy expenditure in anesthetized rats.
abstract: Amylin is a peptide hormone that is co-released with insulin from pancreatic beta-cells following a meal. Intracerebroventricular (icv) administration of amylin (1-100 pmol), or an amylin agonist, salmon calcitonin, elicited dose-dependent thermogenic, tachycardic, and hyperthermic responses in urethane-anesthetized rats. Intravenous (iv) administration of higher doses of amylin (100 pmol-20 nmol) also induced similar responses, although the amplitudes of these responses were significantly smaller than those elicited by icv administration, suggesting the primary action of amylin to be in the brain. However, the iv administration of amylin induced the responses slightly faster than the icv injection, the former responses occurring<4 min and the latter, at 8-10 min, after the administration. The iv but not the icv injection of amylin increased the respiratory exchange ratio transiently (<20 min), though the thermogenic response lasted for a longer period after both injections, indicating a shift from mixed fuel to predominantly carbohydrate utilization in the initial phase of thermogenesis induced by the iv injection of amylin. The differences in substrate utilization and latency of the responses suggest that the actions of amylin include partly different targets when administered centrally and peripherally. Moreover, pretreatment with a beta-adrenergic blocker, propranolol (5 mg kg(-1), iv), blocked all responses elicited by either icv or iv administration of amylin, whereas ablation of the area postrema in the hindbrain did not influence the effects of icv-administered amylin. These results suggest the involvement of amylin in postprandial energy expenditure, mediated by peripheral beta-adrenoceptors.
authors.affiliation: National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku 162-8636, Japan. osaka@nih.go.jp
authors.forename: Toshimasa
authors.initials: T
authors.lastname: Osaka
authors.forename: Ayako
authors.initials: A
authors.lastname: Tsukamoto
authors.forename: Yu
authors.initials: Y
authors.lastname: Koyama
authors.forename: Shuji
authors.initials: S
authors.lastname: Inoue
mesh_terms: D000682:Amyloid / Q000008:administration & dosage / Q000819:agonists / Q000494:pharmacology*; D000818:Animals; D001831:Body Temperature / Q000187:drug effects / Q000502:physiology; D002116:Calcitonin / Q000008:administration & dosage / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004734:Energy Metabolism / Q000187:drug effects* / Q000502:physiology; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D007275:Injections, Intravenous; D007276:Injections, Intraventricular; D058228:Islet Amyloid Polypeptide; D008297:Male; D010101:Oxygen Consumption / Q000187:drug effects; D011433:Propranolol / Q000494:pharmacology; D011659:Pulmonary Gas Exchange / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors
chemical_list: D000682:Amyloid; D058228:Islet Amyloid Polypeptide; C028815:salmon calcitonin; D002116:Calcitonin; D011433:Propranolol